Eyes that photosynthesise: NUS scientists plant a cure for dry eye disease
A nanosized extract of the plant thylakoid grana — the molecular engine behind photosynthesis — is transplanted into the eye's corneal cells, producing a key protective molecule when exposed to ambient light, opening a new front against dry eye disease SINGAPORE, May 16, 2026 /PRNewswire/ -- What if your eyes could use light to heal themselves? Drawing inspiration from...
MINISH Veneers USA Successfully Concludes Biomimetic Veneers Course at VITA North America
LOS ANGELES, , May 16, 2026 /PRNewswire/ -- MINISH Veneers USA successfully concluded its latest U.S. MINISH Veneers Course, held from May 8–10 at the VITA North America Education Center in Brea, California. The three-day continuing education program brought together dental professionals from across North America for intensive hands-on training focused on minimally invasive and biomimetic restorative dentistry. ...
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date. Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors. MELBOURNE, Australia, May 15, 2026 /PRNewswire/ -- Atisama Therapeutics (formerly...
Malaysia Healthcare Week Myanmar 2026 Opens in Yangon with Leading Hospitals Showcasing Specialised Care for Myanmar Patients
YANGON, Myanmar and KUALA LUMPUR, Malaysia, May 15, 2026 /PRNewswire/ -- Malaysia Healthcare Week Yangon 2026 is officially launched today at Park Royal Yangon, bringing together leading Malaysian hospitals to connect directly with Myanmar patients, healthcare professionals, and industry partners. The four-day initiative, led by the Malaysia Healthcare Travel Council (MHTC), comes amid...
Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor patients SYDNEY, May 15, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, today announced that the independent Safety Review Committee (SRC) has completed its review of safety data from Cohort 1 of...
Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be presented as an oral presentation at the 2026 European Hematology Association (EHA) Congress. The abstract is now available on the EHA Congress platform. Ligufalimab is...
Ozelle Wins German Innovation Award Gold for Advancing the Fourth Generation of Hematology Analysis
BERLIN, May 15, 2026 /PRNewswire/ -- Ozelle has received a Gold Award at the German Innovation Award, one of Germany's leading innovation honors, for its EHBT-50 Mini Lab Multi-Functional Analyzer. The award recognizes innovations that advance products and technologies through meaningful user value, engineering excellence, and practical impact across industries. Ozelle Wins German Innovation Award Gold Designed...
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of ‘SNB-101’
SEONGNAM, South Korea, May 15, 2026 /PRNewswire/ -- SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer agent, in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)....
NeuroEndocrine Cancer Australia unveils new website and digital lifeline
NeuroEndocrine Cancer Australia (NECA) has launched a fully updated digital platform designed to improve how the 31,000 Australians affected by neuroendocrine cancer (NETs) access support, information, and specialist care. SYDNEY, May 15, 2026 /PRNewswire/ -- The new website introduces a personalised patient hub experience aimed at helping people navigate every stage of the NET journey, from diagnosis through to...
POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results
GUANGZHOU, China, May 15, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its financial results for the fiscal year ended December 31, 2025. Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "Fiscal year 2025 marked a year of solid revenue expansion...
